5,6-difluoro-2,3-dihydro-1H-inden-2-amine hydrochloride | 173996-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5,6-difluoro-2,3-dihydro-1H-inden-2-amine hydrochloride
• 英文别名: (5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amine hydrochloride；5,6-difluoro-indan-2-ylamine hydrochloride；5,6-difluoro-2,3-dihydro-1H-inden-2-amine;hydrochloride
• CAS: 173996-48-0
• 化学式: C₉H₉F₂N*ClH
• 分子量: 205.635
• InChiKey: AWYTYXIPCLDPNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.81
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5,6-difluoro-2,3-dihydro-1H-inden-2-amine 在 盐酸 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 以19%的产率得到5,6-difluoro-2,3-dihydro-1H-inden-2-amine hydrochloride
  参考文献：
  名称：

  作为阿片样物质受体的拮抗剂或反向激动剂的 新型化合物

  摘要：

  本发明涉及作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物。本发明提供作为一种或多种阿片样物质受体上的拮抗剂或反向激动剂的新型化合物、含有该新化合物的药物组合物及它们的制备方法。

  公开号：

  CN102516115B

文献信息

• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• NOVEL HETEROCYCLE COMPOUNDS
  申请人：Barvian Kevin Karl

  公开号：US20090054431A1

  公开（公告）日：2009-02-26

  The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.

  本发明涉及一种新型化合物，该化合物是阿片受体的拮抗剂或反向激动剂。这些化合物在治疗哺乳动物，特别是人类的肥胖和相关疾病和/或症状中是有用的。还公开了制备和使用这些化合物的方法。
• Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity
  作者：Sreekanth Kokkonda、Xiaoyi Deng、Karen L. White、Jose M. Coteron、Maria Marco、Laura de las Heras、John White、Farah El Mazouni、Diana R. Tomchick、Krishne Manjalanagara、Kakali Rani Rudra、Gong Chen、Julia Morizzi、Eileen Ryan、Werner Kaminsky、Didier Leroy、María Santos Martínez-Martínez、Maria Belen Jimenez-Diaz、Santiago Ferrer Bazaga、Iñigo Angulo-Barturen、David Waterson、Jeremy N. Burrows、Dave Matthews、Susan A. Charman、Margaret A. Phillips、Pradipsinh K. Rathod

  DOI：10.1021/acs.jmedchem.6b00275

  日期：2016.6.9

  Malaria persists as one of the most devastating global infectious diseases. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor I (DSM265) is in clinical development. We sought to identify compounds with higher potency against Plasmodium DHODH while showing greater selectivity toward animal DHODHs. Herein we describe a series of novel triazolopyrimidines wherein the p-SF5-aniline was replaced with substituted 1,2,3,4-tetrahydro-2-naphthyl or 2-indanyl amines. These compounds showed strong species selectivity, and several highly potent tetrahydro-2-naphthyl derivatives were identified. Compounds with halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. falciparum SCID mouse malaria model. These data suggest that tetrahydro-2-naphthyl derivatives have the potential to be efficacious for the treatment of malaria, but due to higher metabolic clearance than 1, they most likely would need to be part of a multidose regimen.
• BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0757677A1

  公开（公告）日：1997-02-12
• PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1943226A2

  公开（公告）日：2008-07-16